Numis Securities restated their buy rating on shares of Puretech Health (LON:PRTC) in a research report released on Tuesday morning. The firm currently has a GBX 259 ($3.58) price objective on the stock.
A number of other equities research analysts have also recently weighed in on PRTC. Peel Hunt restated a buy rating and issued a GBX 278 ($3.84) price objective on shares of Puretech Health in a report on Tuesday, October 31st. Jefferies Group restated a buy rating on shares of Puretech Health in a report on Friday, November 17th. N+1 Singer reiterated a buy rating on shares of Puretech Health in a report on Thursday, November 30th. Finally, Liberum Capital reiterated a buy rating and set a GBX 248 ($3.43) price target on shares of Puretech Health in a report on Friday, January 26th. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and an average price target of GBX 260.20 ($3.59).
Shares of Puretech Health (LON:PRTC) opened at GBX 170.85 ($2.36) on Tuesday. The firm has a market cap of $404.57 and a PE ratio of -899.21. Puretech Health has a fifty-two week low of GBX 110 ($1.52) and a fifty-two week high of GBX 183.50 ($2.54).
Puretech Health Company Profile
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.